Moldova Pharmaceutical Market Q1-Q3 2025: Value Rises 5.5%, Volume Rises 4.6%
- Vlad Chitic
Introduction
The Agency of Medicines and Medical Devices (AMDM) has released its statistical report on the pharmaceutical market of the Republic of Moldova for the first nine months (Q1-Q3) of 2025. The Moldova pharmaceutical market Q1-Q3 2025 data, which covers total imports and local production (excluding the Transnistrian region), reveals a market characterized by steady growth and a continued strong reliance on imported goods.
All data is based on producer prices in EURO, covering total imports and local production (RX and OTC) for the Republic of Moldova, excluding the Transnistrian region.
Key Market Dynamics: Value vs. Volume
The total value of the the Republic of Moldova pharmaceutical market in the first nine months of 2025 reached €204.39 million.
The report highlights two opposing trends when comparing the Q1-Q3 2025 to the same period in 2024:
Value (EUR): The market saw a healthy growth of 5.5%.
Volume (Units): The market experienced a growth of 4.6% in the number of units (boxes) sold, for a total of 74.51 million units (packs).
This difference is explained by a combination of slight price increases and a notable "orientation towards more innovative and, implicitly, more expensive products". The market is also showing a stronger focus on treatments for chronic diseases.
Market Structure: Import vs. Domestic Production
The Republic of Moldova pharmaceutical market continues to be heavily dominated by imported products.
- Imported Medicines: Account for 93% of the market value (€190.07 million) and 85.2% of the volume (63.47 million units).
- Domestic Medicines: Represent 7% of the market value (€14.32 million) and 14.8% of the volume (11.04 million units).
The report notes that while local production's value share is small, it maintains a "positive quantitative trend" , with volume growing from 10.53 million units in 9M 2024 to 11.04 million units in 9M 2025.
Top Countries, Producers, and Products
Imports are primarily sourced from the European Union, with four of the top five partner countries being EU members. Turkey also remains a key manufacturing source.
Top 5 Import Countries (by Value):
Germany: €25.67 million (14%)
Romania: €18.52 million (10%)
Slovenia: €15.97 million (8%)
Hungary: €13.97 million (7%)
Turkiye: €13.87 million (7%)
Top 10 Foreign Producers (by Value):
KRKA: €13.99 million
Gedeon Richter: €11.34 million
Berlin-Chemie: €10.52 million
GlaxoSmithKline: €6.07 million
AstraZeneca: €5.60 million
World Medicine: €5.52 million
Nobel: €5.24 million
Abbot: €4.53 million
Bayer: €4.00 million
Bilim: €3.94 million
Top 5 Local Producers (by Value, doesn't include exports):
SC Balkan Pharmaceuticals SRL: €9.70 million
Farmaprim SRL: €2.60 million
SC Flumed-Farm SRL: €1.20 million
ÎCS Eurofarmaco SA: €0.80 million
ElaDum Pharma SRL: €0.77 million
Top 10 Imported Pharmaceutical Products by INN (by Value):
Dapagliflozinum: €4.72 million
Ibuprofenum: €3.81 million
Rivaroxabanum: €3.12 million
Rosuvastatinum: €2.91 million
Sulodexidum: €2.49 million
Pancreatinum: €2.39 million
Emicizumabum: €2.28 million
Ceftriaxonum: €2.25 million
Medicamentum homeopathicum: €2.18 million
Acidum acetylsalicylicum: €2.09 million
Analysis of Top Imported Products (INN)
The list of top 10 imported products by INN clearly illustrates a market balancing two major priorities:
Modern Chronic Care: A significant portion of the market's value is driven by modern, high-value treatments for diabetes and heart failure (Dapagliflozinum), cardiovascular prevention (Rivaroxabanum, Rosuvastatinum), and high-cost specialty biologics for rare diseases like hemophilia (Emicizumabum).
High-Volume Acute & Self-Care: This advanced segment is balanced by a massive market for common ailments, evidenced by pain and inflammation relief (Ibuprofenum) being the #2 product. The inclusion of a homeopathic product in the top 10 also highlights a strong, consumer-driven segment for self-medication.
Distribution & Market Trends
The influence of the National Health Insurance Company (CNAM) is growing, impacting both imports and local production through its compensated medicines program.
The distribution sector is also seeing continued consolidation, a trend in line with the wider European market. Quality assurance remains a priority, with all licensed distributors in Moldova holding GDP (Good Distribution Practice) certificates or being in the process of certification.
Turn Market Data into Your Market Share
The Q1-Q3 2025 report is clear: the Republic of Moldova pharmaceutical market is growing, specializing, and rewarding innovation. It is an ideal target for manufacturers seeking a stable, value-driven, and import-friendly European market.
However, data is only the beginning. Translating these opportunities into a successful business requires a partner on the ground.
This is where Lismedfarm steps in.
We are not just a service provider; we are your strategic partner for market entry and growth in the Republic of Moldova. This report provides the "what"—we provide the "how."
Lismedfarm can assist your company with a complete suite of solutions for market entry and distribution:
- Registration and Maintenance: Comprehensive support for the initial registration and renewal of medicines, medical devices, and food supplements, including the management of variations and reauthorizations.
- Specialized Services: Pharmacovigilance, manufacturer price registration, and authorized representation for medical devices.
- Market Research and Distribution: Pharmaceutical market analysis, import, warehousing, and national distribution, including sub-distribution for pharmaceutical and parapharmaceutical products.
- Promotion and Sales: Marketing, portfolio promotion, and representation in public health procurement.
Contact Us today to get a detailed analysis of your product portfolio's potential in the the Republic of Moldova market.
You can also consult our Manufacturer's Guide to Moldova's Pharma Market: 2025 Regulations & Statistics.